Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques  

作　　者：Dali Tong Mei Zhang Yunru Yang Han Xia Haiyang Tong Huajun Zhang Weihong Zeng Muziying Liu Yan Wu Huan Ma Xue Hu Weiyong Liu Yuan Cai Yanfeng Yao Yichuan Yao Kunpeng Liu Shifang Shan Yajuan Li Ge Gao Weiwei Guo Yun Peng Shaohong Chen Juhong Rao Jiaxuan Zhao Juan Min Qingjun Zhu Yanmin Zheng Lianxin Liu Chao Shan Kai Zhong Zilong Qiu Tengchuan Jin Sandra Chiu Zhiming Yuan Tian Xue 

机构地区：[1]First Affiliated Hospital of USTC,School of Life Sciences,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230026,China [2]Hefei National Research Center for Physical Sciences at the Microscale,Neurodegenerative Disorder Research Center,CAS Key Laboratory of Brain Function and Disease,CAS Key Laboratory of Innate Immunity and Chronic Disease,Biomedical Sciences and Health Laboratory of Anhui Province,University of Science and Technology of China,Hefei 230026,China [3]State Key Laboratory of Virology,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China [4]Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China [5]Hefei Institutes of Physical Science,Chinese Academy of Sciences,Hefei 230031,China [6]Anhui Institute of Pediatric Research,Anhui Provincial Children's Hospital,Hefei 230051,China [7]Chinese Academy of Sciences Center for Excellence in Brain Science and Intelligence Technology,Chinese Academy of Sciences,Shanghai 200031,China [8]Department of Clinical Laboratory,First Affiliated Hospital of Anhui Medical University,Hefei,230022,China [9]Institute for Stem Cell and Regeneration,Chinese Academy of Sciences,Beijing 100101,China

出　　处：《Protein & Cell》2023年第1期69-73,共5页蛋白质与细胞（英文版）

基　　金：supported by Strategic Priority Research Program of the Chinese Academy of Sciences(XDB39000000 to T.X.);National Natural Science Foundation of China(81925009 to T.X.,81790644 to T.X.,81900855 to M.Z.,82000941 to D.T.);Jack Ma Foundation(2019-nCoV);CAS Project for Young Scientists in Basic Research(YSBR-013);Fundamental Research Funds for the Central Universities(WK5290000001 to Y.C.,WK5290000002 to Y.Y.,WK2090050048 to M.Z.,WK2070000174 to M.Z.);supported by the Anhui Provincial Natural Science Foundation(1808085MH289 to M.Z.).Joint Laboratory of Innovation in Life Sciences from the University of Science and Technology of China(USTC)and Changchun Zhuoyi Biological Co.Ltd.

摘　　要：Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021).

关 键 词：RESPIRATORY ACUTE 

分 类 号：R563.1[医药卫生—呼吸系统]